Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:51am, Monday, 06'th Oct 2025
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
INCY vs. ARGX: Which Stock Is the Better Value Option?
12:41pm, Tuesday, 30'th Sep 2025
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and argenex SE (ARGX). But which of these two companies is the best option for those looking for
SHENZHEN, CHINA, Sept. 28, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”) is pleased to announce that its subsidiaries, Dermavon Holdings Limited (“Dermavon”, an innova
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 24'th Sep 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4).
Cramer reveals 5 undervalued stocks that are must-own heading into 2026
03:15pm, Wednesday, 24'th Sep 2025
Famed investor Jim Cramer says investors shouldn't feel boxed out of the market as the benchmark S&P 500 index continued to print higher highs in the second half of 2025. “Sometimes, it can feel l
Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
07:30am, Monday, 22'nd Sep 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer.
3 Potential Biotech Acquisition Targets
12:53pm, Friday, 19'th Sep 2025
There has been some speculation on Seeking Alpha recently on several biotech/biopharma names that make logical buyout targets. Many firms are on their way to success as standalone entities and have go
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream
10:55am, Friday, 19'th Sep 2025
Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.
US FDA approves Incyte's eczema treatment for pediatric patients
04:29pm, Thursday, 18'th Sep 2025
The U.S. Food and Drug Administration has approved Incyte's eczema treatment for children aged between 2 and 11 years, the company said on Thursday.
Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
04:21pm, Thursday, 18'th Sep 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Additional FDA Approval of Opzelura® (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis.
INCY Announces New Late-Stage Data on Skin Disease Drug
10:41am, Wednesday, 17'th Sep 2025
Incyte's povorcitinib shows strong 24-week STOP-HS data in hidradenitis suppurativa, supporting 2025-2026 regulatory filings.
Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
01:00am, Wednesday, 17'th Sep 2025
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #EADV25--Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025.
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the EADV 2025 Congress.
Incyte Corporation (INCY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
01:46pm, Tuesday, 09'th Sep 2025
Incyte Corporation (NASDAQ:INCY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants William Meury - CEO, President & Director Steven Stein - E
Just What The Doctor Ordered: This Medical Stock Offers Fresh Entry Amid 60% Rally
11:01am, Friday, 05'th Sep 2025
Stocks with healthy profits are usually rewarded with strong price gains. And this medical stock is offering a fresh entry amid a 60% run.
